Subtotal $0.00
Shop Now
Ozempic for PCOS is an off-label use. Semaglutide (Ozempic, Wegovy) is not FDA-approved for polycystic ovary syndrome, and no GLP-1 medicine lists PCOS among its approved uses. The 2023 international PCOS guideline says GLP-1 medicines such as liraglutide and semaglutide could be considered for managing higher weight in adults with PCOS, alongside lifestyle changes and following the same rules as for the general population. Small trials show more weight loss and some drop in testosterone markers than placebo, but the guideline’s own evidence review calls the data very limited. Because pregnancy safety data are lacking, the guideline stresses reliable contraception, and the semaglutide labels say to stop at least 2 months before a planned pregnancy. Decisions belong with an endocrinologist or gynecologist.
Peptide Labs does not sell Ozempic, Wegovy, Mounjaro, Zepbound or any prescription drug. This article summarizes FDA labels, the 2023 guideline and published research. For an overview of how these medicines work, see what GLP-1 is.
Key Takeaways
- No GLP-1 medicine is FDA-approved for PCOS; using Ozempic for it is off-label.
- The 2023 international guideline says GLP-1 drugs could be considered for higher weight in adults with PCOS.
- The guideline's evidence review found the PCOS-specific data very limited.
- Small randomized trials report more weight loss and lower testosterone markers than placebo.
- Pregnancy safety data are lacking; semaglutide labels say to stop at least 2 months before a planned pregnancy.
- Tirzepatide labels warn that it may make birth control pills less reliable for a time.
Can you use Ozempic for PCOS? What the labels say
The Ozempic label (revised May 2026) covers blood sugar control in adults with type 2 diabetes, plus lowering cardiovascular and kidney risks in that group. The Wegovy label (revised June 2026) covers chronic weight management, cardiovascular risk reduction and a liver condition called MASH. PCOS is not on either list, and it is not on the Mounjaro or Zepbound labels either. A prescriber can still choose a medicine for a person with PCOS, for example because that person also has type 2 diabetes or meets the criteria for weight management, but the PCOS itself is not the approved reason.
That distinction matters for expectations. The labels’ benefit data come from trials in people with diabetes or obesity, not from trials designed around PCOS symptoms such as irregular periods, excess hair growth or fertility.
PCOS in brief
The 2023 guideline describes PCOS as the most common hormonal condition in women of reproductive age, affecting an estimated 10% to 13% worldwide. It involves some combination of irregular or absent ovulation, higher androgen (male-type hormone) levels or their signs, and ovaries with many follicles on ultrasound. Insulin resistance and weight gain are common but not universal. PCOS is diagnosed by a clinician using blood tests and other criteria; it cannot be confirmed from symptoms alone.
What the 2023 guideline says about GLP-1 for PCOS
The International Evidence-based Guideline for PCOS, published in 2023 by an international network of experts, makes four points about GLP-1 for PCOS:
- GLP-1 medicines, including liraglutide and semaglutide, and the weight-loss drug orlistat could be considered, together with active lifestyle changes, to manage higher weight in adults with PCOS, following general population guidelines.
- Clinicians should make sure effective contraception is in place when pregnancy is possible, because pregnancy safety data are lacking.
- The strength should be increased gradually to reduce digestive side effects.
- Shared decision-making should weigh side effects, the possible need for long-term use, the high risk of weight regain after stopping and the lack of long-term safety data.
The guideline still recommends lifestyle changes for everyone with PCOS. For irregular cycles and excess hair it generally favors combined birth control pills, and for metabolic concerns it favors metformin. GLP-1 medicines are positioned as a weight-management option, not as a PCOS medicine.
Semaglutide PCOS research: the trials so far
Most semaglutide PCOS studies are small, short and often funded or supported by the manufacturer. The table summarizes the better-controlled evidence.
| Study | Who and how long | Main findings | Notes |
|---|---|---|---|
| Liraglutide randomized trial (Fertility and Sterility, 2022) | 82 women with obesity and PCOS, 32 weeks, plus lifestyle program | Weight down 5.7% vs 1.4% on placebo; free androgen index fell; digestive side effects 58% vs 19% | Hospital-sponsored, Novo Nordisk collaborator |
| Meta-analysis of 4 randomized trials (2024) | 176 women with PCOS and obesity | BMI, waist size, triglycerides and total testosterone lower than placebo; no difference in an insulin resistance score | Only 23 people took semaglutide |
| Guideline evidence review (Obesity Reviews, 2024) | 11 trials of weight-loss drugs in PCOS | Liraglutide, semaglutide and orlistat appeared better than placebo for weight measures | Authors call the data very limited |
| Semaglutide taste study (2025) | 30 women with PCOS and obesity, 16 weeks | Taste recognition and brain responses to food cues changed | Mechanism study, not an outcome trial |
None of these trials was large or long enough to show effects on live births, diabetes onset or heart disease in people with PCOS. Reports of lower testosterone and better cycles are interesting, but it is not clear how much comes from the weight loss itself. Our summary of weight-loss results in the main GLP-1 trials shows what the larger obesity trials found.
Wegovy PCOS questions: fertility, pregnancy and birth control
People often ask about Wegovy PCOS use when they are thinking about pregnancy. Online stories of unexpected pregnancies on GLP-1 medicines exist, and weight loss can restore ovulation in some women with PCOS, but no trial has shown that these medicines improve fertility or live birth rates in PCOS. The label facts point toward caution:
- Semaglutide: the Ozempic and Wegovy labels say to stop the medicine at least 2 months before a planned pregnancy because semaglutide stays in the body for a long time. The Wegovy Medication Guide says it may harm an unborn baby, and a pregnancy exposure registry collects outcomes.
- Tirzepatide: the Mounjaro and Zepbound labels (revised August 2026) say tirzepatide may reduce how well birth control pills work because it slows stomach emptying. They advise switching to a non-oral method or adding a barrier method for a period after starting and after each step up. Hormonal contraceptives that are not taken by mouth should not be affected.
- The guideline: effective contraception whenever pregnancy is possible, since pregnancy safety data are lacking.
Anyone planning a pregnancy, or already pregnant, should talk to their prescriber before making any change to the medicine.
How GLP-1 medicines sit beside other PCOS options
- Metformin has a longer research record in PCOS than GLP-1 drugs, although PCOS is not on its label either; see what the metformin research shows.
- Inositol is a supplement studied in PCOS; the guideline calls its clinical benefits limited and says no form or ratio can be recommended. Our inositol explainer covers the trials.
- Berberine has been tested in small PCOS trials from a few centers; see what the berberine research shows. Neither supplement is a substitute for medical care.
Side effects and who should not use semaglutide
Semaglutide carries a boxed warning about thyroid C-cell tumors seen in rodents and must not be used by people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2. Nausea, vomiting, diarrhea and constipation are the most common effects, and the labels warn about pancreatitis, gallbladder problems and kidney injury from dehydration. Details are in our guides to semaglutide side effects and tirzepatide side effects, and eating on a GLP-1 medicine covers nutrition.
When to see a specialist
See a clinician to confirm a PCOS diagnosis, and an endocrinologist or gynecologist to weigh options, especially if you have type 2 diabetes, a family history of thyroid cancer, a history of pancreatitis or an eating disorder, or plans for pregnancy. Bring a list of every medicine and supplement you take.
Frequently Asked Questions
Is Ozempic approved for PCOS?
No. Ozempic is approved for type 2 diabetes and related heart and kidney risks. Using it for PCOS is off-label, and no GLP-1 medicine lists PCOS as an approved use.
What does the PCOS guideline say about GLP-1 for PCOS?
The 2023 international guideline says GLP-1 medicines could be considered for higher weight in adults with PCOS, alongside lifestyle changes, with effective contraception and a discussion of long-term use.
Does semaglutide help PCOS symptoms?
Small trials report more weight loss and lower testosterone markers than placebo. Evidence on periods, hair growth and fertility is limited, and long-term data are lacking.
Can Ozempic help me get pregnant with PCOS?
No trial has shown that. Weight loss can restore ovulation in some women, but the labels say to stop semaglutide at least 2 months before a planned pregnancy.
Does Mounjaro affect birth control pills?
Its label says tirzepatide may make birth control pills less reliable for a period after starting and after each step up, and advises a non-oral or backup barrier method.
Is Ozempic better than metformin for PCOS?
There is no large head-to-head answer. The guideline favors metformin for metabolic concerns and positions GLP-1 drugs as a weight-management option.
Peptide Labs does not sell GLP-1 medicines or any prescription drug. This article is general information, not medical advice. Read the Medication Guide that comes with a prescription, and ask a pharmacist or prescriber how this information applies to you.
Last reviewed October 2026.
Related guides: Inositol: Myo-Inositol, D-Chiro-Inositol and What Research Shows, Metformin for Weight Loss: What the Evidence Shows, GLP-1 for Weight Loss: What the Trials Actually Showed.